

NEWS RELEASE

Kuala Lumpur/Singapore, 28 November 2024

IHH Healthcare reports higher core net profit for Q3 2024

- **Q3 2024:** PATMI (ex EI) up 43% on higher patient volumes and taking on more complex cases; paid out interim dividend of 4.5 sen per share
- **YTD 2024:** strong core operational performance with double-digit growth across revenue, EBITDA, and PATMI (ex EI)
- **Reinforcing healthcare leadership:** largest private healthcare provider to implement CDC guidelines on antimicrobial stewardship; adding close to 1,000 beds to better serve patients

“We delivered solid core performance for Q3 2024 and year to date as we improved inpatient volumes and revenue intensity.

As part of our commitment to elevating care and clinical excellence, we are proud to be the largest private healthcare provider in the world to implement CDC guidelines for managing antimicrobial resistance, across our network of more than 80 hospitals across 10 markets. This goes a long way towards enhancing patient wellbeing and safety.

We also strengthened our leadership position in key markets by acquiring Island Hospital in Penang and opening Fortis Hospital, Manesar in the National Capital Region (“NCR”), India. This adds a combined 1,000 beds and allows us to extend our exceptional care to significantly more patients.

As we continue to execute on our strategic priorities and placing patients at the centre of all we do, we remain confident of our growth trajectory.”

Dr Prem Kumar Nair
Group Chief Executive Officer, IHH Healthcare

GROUP RESULTS – FINANCIAL HIGHLIGHTS¹
Q3 2024 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
RM5.6b	RM1.3b	RM528m	RM534m
-3%	-9%	+43%	flat

YTD 2024 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
RM17.7b	RM4.0b	RM1.4b	RM1.9b
+13%	+12%	+35%	-13%

¹ The Group's headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.

GROUP OPERATIONAL SUMMARY
(FOR QUARTER ENDED 30 SEPTEMBER 2024)



Occupancy

(for Q3 2024)

73%



Inpatient Admissions

(for Q3 2024)

232,071



Operational Beds

(as at 30 September 2024)

12,220



Lab Tests

(for Q3 2024)

27 million

Q3 2024: Strong core net profit growth on sustained demand for quality healthcare services and revenue intensity growth


- Revenue and EBITDA were lower at RM5.6 billion and RM1.3 billion respectively. Across all key markets, IHH saw higher inpatient volumes as well as revenue intensity from taking on more complex cases. Excluding the effects of MFRS 129, revenue and EBITDA would have grown by 10% and 7% respectively.
- PATMI was flat against last year. Excluding exceptional items, PATMI (ex EI) was up 43% on core operational growth.
- Paid out interim dividend of 4.5 sen per share on 30 Oct 2024.
- To further elevate itself as a global healthcare leader, IHH has in recent months:
 - Become the largest international private hospital network to implement Centers for Disease Control and Prevention (“CDC”) guidelines for its Antimicrobial Stewardship Program (“ASP”), to optimise the use of antibiotics, prevent superbug infections and enhance patient safety.
 - Strengthened leading position in key markets by adding close to 1,000 beds through strategic acquisition of the 600-bed Island Hospital in Penang and commencing operations at the 350-bed Fortis Hospital, Manesar in NCR, India.

YTD 2024: Sustained core operational growth; strong financial position

- Revenue and EBITDA reported double-digit growth on sustained growth in patient volumes and revenue intensity across all markets, at 13% and 12% respectively.
- The lower headline PATMI was primarily due to a high base last year, which recorded one-off gains of RM873.0 million from the sale of International Medical University (“IMU”).
- Excluding exceptional items, PATMI (ex EI) grew by 35%.
- Balance sheet remained strong: net cash generated from operating activities at RM3.1 billion; net gearing at healthy 0.24x.

GROUP OUTLOOK

The ACE framework will continue to guide IHH's growth across five strategic priorities:



- With growing healthcare needs both locally and from around the region, The Group is confident of its trajectory. It will anchor on its ACE framework to deliver against its five strategic priorities, notably aiming to add close to 4,000 new beds in the next five years.
- Overall, the Group expects continued revenue growth fuelled by healthcare megatrends and will focus on driving profitability and sustaining healthy ROE while maintaining prudent capital management and mitigating inflationary and interest rates pressures.

+++

ABOUT IHH HEALTHCARE BERHAD (“IHH”)

A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good.

Our team of more than 70,000 people commit to deliver greater good to our patients, people, the public and planet, as we live our purpose each day to touch lives and transform care.

Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Island Hospital, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation.

With our scale and reach in 10 countries, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Türkiye, India, Greater China (including Hong Kong) and beyond.

In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to become the world's most trusted healthcare services network.

More information can be found at www.ihhhealthcare.com.

+++

For more information or to speak to an IHH spokesperson, please contact:

Kelvin Chong
Investor Relations, IHH Healthcare
t. +65 9489 5357
e. kelvin.chong@ihhhealthcare.com

Melissa Sim
WATATAWA Consulting
t. +65 9380 2938
e. msim@we-watatawa.com